MIRADX

MiraDx is developing more panels of biomarkers to apply before radiation therapy treatment to identify patients who have different sensitivities and responses to radiation therapy. These tests make much needed strides towards personalizing radiotherapy... MiraDx is creating biomarker panels to predict both toxicity (immune-related adverse events (iRAEs)) as well as response to the developing immunotherapies. Their first test predicts iRAEs to anti-PD1/PDL1 therapy across all cancer types. So, patients with any type of cancer who are being considered for this therapy are eligible for testing... Our cutting-edge genetic research discovered a new class of genetic biomarkers that can dramatically change personalized treatment.

Also known as: MiraDx Inc.

Primary location: Los Angeles United States